NEW YORK (360Dx) – Oxford Immunotec today announced that the US District Court for the District of Massachusetts has denied its motion for a preliminary injunction prohibiting the sale to new customers in the US of Qiagen's QuantiFERON-TB Gold Plus (QFT Plus), a test used for the detection of latent tuberculosis.

Oxford said that the decision was based on the court's belief that it was not likely to suffer irreparable harm from Qiagen's marketing of QFT-Plus before an upcoming trial in January.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.